Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

SCHERING-PLOUGH

(SGP)
SummaryNewsCompany 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

SCHERING-PLOUGH : Declares Quarterly Dividends on Common Shares and Mandatory Convertible Preferred Stock

09/18/2009 | 11:45am EDT

KENILWORTH, N.J., Sept. 18 /PRNewswire-FirstCall/ -- The Board of Directors of Schering-Plough Corporation (NYSE: SGP) today declared a quarterly dividend of 6.5 cents per common share. Payment will be made on Nov. 30, 2009, to shareholders of record at the close of business on Oct. 26, 2009. As of June 30, 2009, there were 1,633,938,697 common shares outstanding.

The Board of Directors today also declared a quarterly dividend of $3.75 per share on the 2007 Mandatory Convertible Preferred Stock. Payment will be made on Nov. 16, 2009, to holders of record at the close of business on November 2, 2009. There are currently 10 million shares of 2007 Mandatory Convertible Preferred Stock outstanding.

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription, animal health and consumer health care products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is www.schering-plough.com.

SOURCE Schering-Plough Corporation


© PRNewswire 2009
All news about SCHERING-PLOUGH
2009SCHERING-PLOUGH : Announces Sponsorship of Rabies-Control Projects in India
PR
2009SCHERING-PLOUGH : Investigational Sublingual Allergy Immunotherapy Tablet Meets ..
PR
2009SCHERING-PLOUGH : U.S. Food and Drug Administration Issues Complete Response Let..
PR
2009SCHERING-PLOUGH : Standard & Poor's Announces Changes to U.S. Indices
PR
2009SCHERING-PLOUGH : Reports Financial Results for 2009 Third Quarter
PR
2009SCHERING-PLOUGH : Nobilon Advances Intranasal Seasonal Influenza Vaccine Into Pr..
PR
2009SCHERING-PLOUGH : Schedules Conference Call Webcast For 2009 Third Quarter Earni..
PR
2009SCHERING-PLOUGH : SIMPONI(TM) (golimumab) Receives European Approval as Once-Mon..
PR
2009SCHERING-PLOUGH : Declares Quarterly Dividends on Common Shares and Mandatory Co..
PR
2009SCHERING-PLOUGH : Reports Long-Term Vicriviroc Data From Phase II Open-Label Ext..
PR
More news